Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
We can't give an honest read on this one right now.
Our model values a company on the cash it can hand its owners after paying for its own growth. For Humana that number is not something we can compute today — so rather than estimate around the gap, we are leaving it blank until the next filings close it.
Why not
- Caution: What is missingHumana's free cash flow fell to about $0.4B in 2025, roughly 85% below its own five-year norm, as Medicare Advantage reimbursement rates were cut, medical costs ran ahead of premiums and the company lost members and star-rating bonuses. Our fair value normalizes a one-off bad year back to typical cash flow, but this looks like a reset to a lower level of profitability rather than a single bad year — and normalizing against a median that still contains the higher-margin years would overstate what the business now earns. The read returns once a full year has been filed at the repriced margins and a five-year base can be drawn from them.
Why show the page at all. Because the alternative is a number we don't believe. Every other company on TickerMath gets a fair value computed from its SEC filings; this one gets a plain explanation instead, which is the same promise kept a different way. This one is expected to change: we re-test every company against its new filings, and the read appears here as soon as the figures support it.
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →